跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

G8147

Sigma-Aldrich

胰高血糖素样肽 Ⅰ 酰胺片段 7-36 人

≥97% (HPLC), powder

别名:

前胰高血糖素原 78-107 酰胺

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C149H226N40O45
CAS号:
107444-51-9
分子量:
3297.63
MDL號碼:
MFCD00133373
分類程式碼代碼:
51111800
PubChem物質ID:
329799974
NACRES:
NA.32

品質等級

200

化驗

≥97% (HPLC)

形狀

powder

UniProt登錄號

P01275

儲存溫度

−20°C

SMILES 字串

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc4c[nH]cn4)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc5c[nH]c6ccccc56)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O

InChI

1S/C149H226N40O45/c1-17-76(10)119(146(232)167-80(14)126(212)175-104(60-86-63-159-91-36-25-24-35-89(86)91)136(222)177-100(56-73(4)5)137(223)186-117(74(6)7)144(230)174-93(37-26-28-52-150)128(214)160-65-110(197)168-92(122(154)208)39-30-54-158-149(155)156)188-138(224)102(57-83-31-20-18-21-32-83)178-133(219)98(47-51-115(204)205)173-132(218)94(38-27-29-53-151)170-124(210)78(12)164-123(209)77(11)166-131(217)97(44-48-109(153)196)169-111(198)66-161-130(216)96(46-50-114(202)203)172-134(220)99(55-72(2)3)176-135(221)101(59-85-40-42-88(195)43-41-85)179-141(227)106(68-190)182-143(229)108(70-192)183-145(231)118(75(8)9)187-140(226)105(62-116(206)207)180-142(228)107(69-191)184-148(234)121(82(16)194)189-139(225)103(58-84-33-22-19-23-34-84)181-147(233)120(81(15)193)185-112(199)67-162-129(215)95(45-49-113(200)201)171-125(211)79(13)165-127(213)90(152)61-87-64-157-71-163-87/h18-25,31-36,40-43,63-64,71-82,90,92-108,117-121,159,190-195H,17,26-30,37-39,44-62,65-70,150-152H2,1-16H3,(H2,153,196)(H2,154,208)(H,157,163)(H,160,214)(H,161,216)(H,162,215)(H,164,209)(H,165,213)(H,166,217)(H,167,232)(H,168,197)(H,169,198)(H,170,210)(H,171,211)(H,172,220)(H,173,218)(H,174,230)(H,175,212)(H,176,221)(H,177,222)(H,178,219)(H,179,227)(H,180,228)(H,181,233)(H,182,229)(H,183,231)(H,184,234)(H,185,199)(H,186,223)(H,187,226)(H,188,224)(H,189,225)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,155,156,158)/t76-,77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,117-,118-,119-,120-,121-/m0/s1

InChI 密鑰

DTHNMHAUYICORS-KTKZVXAJSA-N

基因資訊

human ... GCG(2641)

正在寻找类似产品? 访问 产品对比指南

Amino Acid Sequence

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2

一般說明

胰高血糖素样肽 1 (GLP-1) 肽来自胰高血糖素原，无代谢活性。不过它可被加工成两种较小的酰胺形式，即 GLP-1 (7-37) 酰胺和 GLP-1 (7-36) 酰胺。它是一种天然的胃肠肽。

應用

人胰高血糖素样肽 I 酰胺片段 7-36 在 DMEM (Dulbeccos) 培养基中用于培养 3T3-L1 脂肪细胞，以研究脂肪组织 GLP-1 受体与肥胖和胰岛素抵抗之间的关系。
人胰高血糖素样肽(GLP)I 7-36酰胺片段作为GLP-1受体激动剂的应用实例：
  • 在裂解物环磷酸腺苷(cAMP)荧光能量共振转移法中检测其对腺苷酸环化酶活性的影响
  • 预处理人脐静脉内皮细胞(HUVEC)，以便检测其对内皮细胞(EC)高渗透性和肌动蛋白细胞骨架变化的影响
  • 检测其对大鼠肠系膜动脉中基于血管内皮生长因子-A(VEGFA)的血管舒张的影响

生化／生理作用

GLP-1（胰高血糖素样肽 1）(7-36) 酰胺是一种强效促胰岛素分泌肽，可启动餐后或口服葡萄糖后葡萄糖诱导的胰岛素释放。它具有抗糖尿病作用，因此可能用于治疗非胰岛素依赖型糖尿病。

其他說明

冻干自H2O 0.1% TFA

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sibel Ozyazgan et al.
Pharmacology, 74(3), 119-126 (2005-03-05)
We investigated the vascular effects of glucagon-like peptide-1 (GLP-1) and Exendin-4 in type 2 diabetic rat aortae. Studies were performed in a normal control group (NC) (0.2 ml i.p. saline, n = 10), streptozotocin (STZ)/nicotinamide diabetic control group (DC) (a
Sang-Heon Lee et al.
Bioconjugate chemistry, 16(2), 377-382 (2005-03-17)
Glucagon-like peptide-1-(7-36) (GLP-1) is a hormone derived from the proglucagon molecule, which is considered a highly desirable antidiabetic agent mainly due to its unique glucose-dependent stimulation of insulin secretion profiles. However, the development of a GLP-1-based pharmaceutical agent has a
An osmotic stimulus-mediating glucagon-like peptide-1 (7-36 amide) (GLP-1) secretion in acarbose-induced sucrose malabsorption?
L Ranganath et al.
Nutrition (Burbank, Los Angeles County, Calif.), 16(1), 64-65 (2000-02-16)
Marc Claret et al.
Obesity research, 12(10), 1596-1603 (2004-11-13)
To investigate the effect of S 23521, a new glucagon-like peptide-1-(7-36) amide analogue, on food intake and body weight gain in obese rats, as well as on gene expression of several proteins involved in energy homeostasis. Lean and diet-induced obese
Raik Wolf et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 803(1), 91-99 (2004-03-18)
The incretins, glucose-dependent insulinotropic peptide (GIP(1-42)) and glucagon-like peptide 1 (GLP-1(7-36)), are involved in regulation of gastric emptying, glucose homeostasis, body fat regulation and the glucose-induced insulin secretion from the endocrine pancreas. After release in the circulation both peptides are
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门